Lupin has informed about submission of a Press Release as regards receipt of USFDA approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg, to market a generic version of SpecGx LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg. It is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.